(NATR) Natures Sunshine Products - Ratings and Ratios
Nutritional Products, Personal Care Products, Health Supplements
NATR EPS (Earnings per Share)
NATR Revenue
Description: NATR Natures Sunshine Products
Natures Sunshine Products, Inc. is a leading natural health and wellness company that develops and markets a diverse range of nutritional and personal care products globally, operating in multiple regions including Asia, Europe, North America, and Latin America. The companys product portfolio is comprehensive, covering various health categories such as immune support, cardiovascular health, digestive health, and weight management, among others.
From a business perspective, NATR operates through a direct-to-consumer model, utilizing a network of independent consultants to distribute its products under the Natures Sunshine Products and Synergy WorldWide brands. This approach allows the company to maintain a strong connection with its customer base while leveraging the sales capabilities of its independent distributors.
Key Performance Indicators (KPIs) that could be of interest include revenue growth, gross margin ratio, and operating expense as a percentage of revenue. Given NATRs business model, metrics such as the number of active independent consultants, customer retention rates, and product diversification could also provide valuable insights into the companys operational efficiency and market competitiveness. Additionally, monitoring the companys investment in research and development, as well as its commitment to quality and regulatory compliance, could offer a more comprehensive understanding of its long-term sustainability.
From a financial standpoint, NATRs market capitalization and price-to-earnings ratio suggest a certain level of investor confidence. The companys return on equity (RoE) of 6.49% indicates that it is generating a relatively modest return on shareholders equity, which could be an area for improvement. Analyzing NATRs financial leverage, interest coverage ratio, and cash flow generation could further elucidate its financial health and ability to invest in growth initiatives.
NATR Stock Overview
| Market Cap in USD | 291m |
| Sub-Industry | Personal Care Products |
| IPO / Inception | 2009-06-25 |
NATR Stock Ratings
| Growth Rating | 30.2% |
| Fundamental | 65.2% |
| Dividend Rating | 1.94% |
| Return 12m vs S&P 500 | 6.31% |
| Analyst Rating | 5.0 of 5 |
NATR Dividends
Currently no dividends paidNATR Growth Ratios
| Growth Correlation 3m | 77.1% |
| Growth Correlation 12m | 31.2% |
| Growth Correlation 5y | -6.2% |
| CAGR 5y | 10.06% |
| CAGR/Max DD 5y | 0.16 |
| Sharpe Ratio 12m | -0.47 |
| Alpha | 11.97 |
| Beta | 0.779 |
| Volatility | 39.39% |
| Current Volume | 63.5k |
| Average Volume 20d | 127.2k |
| Stop Loss | 16.1 (-4.5%) |
| Signal | 1.86 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (14.1m TTM) > 0 and > 6% of Revenue (6% = 27.6m TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA 0.04pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 20.83% (prev 20.01%; Δ 0.82pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 21.7m > Net Income 14.1m (YES >=105%, WARN >=100%) |
| Net Debt (-65.7m) to EBITDA (36.0m) ratio: -1.83 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.27 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (19.0m) change vs 12m ago -0.80% (target <= -2.0% for YES) |
| Gross Margin 71.77% (prev 71.18%; Δ 0.59pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 187.8% (prev 187.3%; Δ 0.53pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 476.2 (EBITDA TTM 36.0m / Interest Expense TTM 45.0k) >= 6 (WARN >= 3) |
Altman Z'' 5.74
| (A) 0.38 = (Total Current Assets 171.8m - Total Current Liabilities 75.9m) / Total Assets 254.9m |
| (B) 0.26 = Retained Earnings (Balance) 67.5m / Total Assets 254.9m |
| (C) 0.09 = EBIT TTM 21.4m / Avg Total Assets 245.4m |
| (D) 1.73 = Book Value of Equity 157.7m / Total Liabilities 91.2m |
| Total Rating: 5.74 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 65.17
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 6.95% = 3.47 |
| 3. FCF Margin 3.47% = 0.87 |
| 4. Debt/Equity 0.13 = 2.49 |
| 5. Debt/Ebitda 0.55 = 2.27 |
| 6. ROIC - WACC -2.50% = -3.13 |
| 7. RoE 8.94% = 0.75 |
| 8. Rev. Trend 72.65% = 3.63 |
| 9. Rev. CAGR 3.46% = 0.43 |
| 10. EPS Trend 35.72% = 0.89 |
| 11. EPS CAGR 233.2% = 2.50 |
What is the price of NATR shares?
Over the past week, the price has changed by +2.74%, over one month by +15.02%, over three months by +10.20% and over the past year by +24.35%.
Is Natures Sunshine Products a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NATR is around 15.29 USD . This means that NATR is currently overvalued and has a potential downside of -9.26%.
Is NATR a buy, sell or hold?
- Strong Buy: 2
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the NATR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 21.5 | 27.6% |
| Analysts Target Price | 21.5 | 27.6% |
| ValueRay Target Price | 17 | 1% |
Last update: 2025-08-29 04:44
NATR Fundamental Data Overview
CCE Cash And Equivalents = 81.3m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 22.0267
P/E Forward = 16.8634
P/S = 0.6322
P/B = 1.8477
Beta = 1.124
Revenue TTM = 460.8m USD
EBIT TTM = 21.4m USD
EBITDA TTM = 36.0m USD
Long Term Debt = 15.3m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 4.62m USD (from shortTermDebt, last quarter)
Debt = 20.0m USD (Calculated: Short Term 4.62m + Long Term 15.3m)
Net Debt = -65.7m USD (from netDebt column, last quarter)
Enterprise Value = 230.0m USD (291.3m + Debt 20.0m - CCE 81.3m)
Interest Coverage Ratio = 476.2 (Ebit TTM 21.4m / Interest Expense TTM 45.0k)
FCF Yield = 6.95% (FCF TTM 16.0m / Enterprise Value 230.0m)
FCF Margin = 3.47% (FCF TTM 16.0m / Revenue TTM 460.8m)
Net Margin = 3.06% (Net Income TTM 14.1m / Revenue TTM 460.8m)
Gross Margin = 71.77% ((Revenue TTM 460.8m - Cost of Revenue TTM 130.1m) / Revenue TTM)
Tobins Q-Ratio = 1.46 (Enterprise Value 230.0m / Book Value Of Equity 157.7m)
Interest Expense / Debt = 0.12% (Interest Expense 24.0k / Debt 20.0m)
Taxrate = 57.17% (from yearly Income Tax Expense: 10.5m / 18.4m)
NOPAT = 9.18m (EBIT 21.4m * (1 - 57.17%))
Current Ratio = 2.27 (Total Current Assets 171.8m / Total Current Liabilities 75.9m)
Debt / Equity = 0.13 (Debt 20.0m / last Quarter total Stockholder Equity 157.7m)
Debt / EBITDA = 0.55 (Net Debt -65.7m / EBITDA 36.0m)
Debt / FCF = 1.25 (Debt 20.0m / FCF TTM 16.0m)
Total Stockholder Equity = 157.7m (last 4 quarters mean)
RoA = 5.53% (Net Income 14.1m, Total Assets 254.9m )
RoE = 8.94% (Net Income TTM 14.1m / Total Stockholder Equity 157.7m)
RoCE = 12.38% (Ebit 21.4m / (Equity 157.7m + L.T.Debt 15.3m))
RoIC = 5.82% (NOPAT 9.18m / Invested Capital 157.7m)
WACC = 8.32% (E(291.3m)/V(311.3m) * Re(8.89%)) + (D(20.0m)/V(311.3m) * Rd(0.12%) * (1-Tc(0.57)))
Shares Correlation 5-Years: -80.0 | Cagr: -1.45%
Discount Rate = 8.89% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 69.00% ; FCFE base≈15.5m ; Y1≈11.2m ; Y5≈6.20m
Fair Price DCF = 5.82 (DCF Value 102.7m / Shares Outstanding 17.6m; 5y FCF grow -32.63% → 3.0% )
Revenue Correlation: 72.65 | Revenue CAGR: 3.46%
Rev Growth-of-Growth: -0.49
EPS Correlation: 35.72 | EPS CAGR: 233.2%
EPS Growth-of-Growth: -64.22
Additional Sources for NATR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle